An error has occurred. An error has occurred.
 

Hiking, biking, snow skiing, water skiing, kayaking and playing music are just a few of the activities that Todd and his family enjoy on a regular basis. So, at only 42 years old, Todd never expected he'd be diagnosed with advanced prostate cancer. With four children, five grandchildren, and a new wife, he had too much to live for to give up. Todd worked vigilantly with his physicians to come up with a treatment plan that included PROVENGE (sipuleucel-T). After initial treatments stopped working and his cancer progressed, Todd received PROVENGE in mid-2012. Never taking life for granted, Todd truly enjoys the adventures he shares with his family and his hope for the future remains strong.

 
 

As a fifth-grade teacher with three children and two grandchildren, Tim is always on the move, whether he's teaching, surfing, cycling, or enjoying the outdoors with his family. Tim never thought he'd be battling prostate cancer at 52 years old. After the initial shock of diagnosis, he decided he couldn't let prostate cancer slow him down. When his cancer spread after two years of treatment, his doctor recommended PROVENGE (sipuleucel-T), which he received in early in 2012. Tim's fifth-grade students still keep his life busy, but his family helps him live it to the fullest.

 
 
Provenge.com

PROVENGE® (sipuleucel-T) is the first and only FDA-approved immunotherapy for advanced prostate cancer. PROVENGE takes the body’s own immune cells and reprograms them to attack advanced prostate cancer.

LEARN
MORE >>

 
OUR PRODUCT PLATFORM

PROVENGE is different from other kinds of prostate cancer medicine. To see how PROVENGE is manufactured and designed to work, watch a video that explains the PROVENGE process.

HOW PROVENGE IS MADE>>

 
COMPANY INFORMATION

Dendreon has reached agreements with certain of its senior noteholders on the terms of a financial restructuring. Operations will continue in the ordinary course and PROVENGE will remain available.

 

INDICATION: PROVENGE® (sipuleucel-T) is approved by the FDA as an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
Important Safety Information | Full Prescribing Information